Literature DB >> 1488404

Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure.

Y H Lee1, M H Lee, C K Shim.   

Abstract

The effect of uranyl nitrate (UN)-induced acute renal failure (ARF) on the pharmacokinetics of diltiazem (DTZ) was examined in rats through in vitro and in vivo studies. In vitro homogenate studies demonstrated that DTZ was metabolized to deacetyl diltiazem (DAD) predominantly in the liver. Metabolism in the small intestine, kidney, or blood pool was negligible compared with that in the liver. UN-induced ARF (UN-ARF) increased the in vitro hepatic clearance (CLvit) of DTZ 1.4-fold. In vivo pharmacokinetic studies following intravenous (iv) and portal venous (pv) administration revealed that UN-ARF increased the intrinsic clearance (CLi) of DTZ from 243.0 to 414.5 ml/min/kg but decreased its total plasma clearance (CLt) from 90.3 to 64.3 ml/min/kg. The increase in CLi was consistent with the increase in CLvit of the liver. The in vitro plasma free fraction of DTZ (fp) was decreased from 0.25 to 0.14 by UN-ARF, but the in vitro blood/plasma partition of DTZ (Rb) remained constant at unity. From the CLi and fp changes, the plasma intrinsic clearance for unbound DTZ (CLi') was calculated to be increased 2.7-fold, from 1104.5 to 2960.7 ml/min/kg, by UN-ARF. The fp decrease was also reflected in the steady-state distribution volume (Vdss) of DTZ, which was decreased significantly from 3595.5 to 2528.3 ml/kg. The absolute bioavailability of pv DTZ (Fpv) was decreased by UN-ARF from 37.5 to 15.5% but was still much higher than the reported oral bioavailability (6%), indicating poor absorption of DTZ from the GI tract. From the calculation based on a well-stirred pharmacokinetic model, DTZ was found to increase the hepatic blood flow (HBF) of the control rats more than twofold at doses of 3 mg/kg (iv) or 10 mg/kg (pv), possibly due to the vasodilating effect of DTZ. However, the effect of DTZ on HBF was not present in the UN-ARF rats. It is not clear at present whether this could be attributed to vasoconstricting effects of UN-ARF or blockade of the vasodilating effect of DTZ.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1488404     DOI: 10.1023/a:1015868525978

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  High-performance liquid chromatographic determination of diltiazem and its major metabolites, N-monodemethyldiltiazem and desacetyldiltiazem, in plasma.

Authors:  S C Montamat; D R Abernethy; J R Mitchell
Journal:  J Chromatogr       Date:  1987-03-20

2.  Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function.

Authors:  J Rieder; D E Schwartz; M Fernex; T Bergan; E K Brodwall; A Blumberg; P Cottier; W Scheitlin
Journal:  Antibiot Chemother (1971)       Date:  1974

3.  Plasma turnover of methyldopa in advanced renal failure.

Authors:  E Myhre; E K Brodwall; O Stenbaek; T Hansen
Journal:  Acta Med Scand       Date:  1972-04

4.  Hepatic clearance of indocyanine green during the course of glycerol-induced acute renal failure in the rat.

Authors:  M S Yates; J Emmerson; C J Bowmer
Journal:  J Pharm Pharmacol       Date:  1983-05       Impact factor: 3.765

5.  [Interactions by diltiazem (3). Mechanism of enhancement of propranolol absorption by diltiazem].

Authors:  A Etoh; H Yamakita; K Kohno; T Nagao; T Ikeo
Journal:  Yakugaku Zasshi       Date:  1983-05       Impact factor: 0.302

6.  Digitoxin kinetics in patients with impaired renal function.

Authors:  K Rasmussen; J Jervell; L Storstein; K Gjerdrum
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

7.  Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline.

Authors:  J Fabre; J de Freudenreich; A Duckert; J S Pitton; M Rudhardt; C Virieux
Journal:  Helv Med Acta       Date:  1967-01

8.  Pentobarbital elimination in patients with poor renal function.

Authors:  M M Reidenberg; D T Lowenthal; W Briggs; M Gasparo
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

9.  Pharmacokinetics and metabolism of diltiazem in man.

Authors:  V Rovei; R Gomeni; M Mitchard; J Larribaud; C Blatrix; J J Thebault; P L Morselli
Journal:  Acta Cardiol       Date:  1980       Impact factor: 1.718

10.  Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog.

Authors:  S Nakamura; T Suzuki; Y Sugawara; S Usuki; Y Ito; T Kume; M Yoshikawa; H Endo; M Ohashi; S Harigaya
Journal:  Arzneimittelforschung       Date:  1987-11
View more
  6 in total

Review 1.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

2.  Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure.

Authors:  S H Kim; H J Shim; W B Kim; M G Lee
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.

Authors:  Y H Lee; B A Perry; H S Lee; J R Kunta; J P Sutyak; P J Sinko
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

4.  Deacetylation of diltiazem by several rabbit tissues.

Authors:  L J Fraile; J J Aramayona; M A Bregante; M A García; A R Abadía
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Pharmacokinetics of etoposide in rats with uranyl nitrate (UN)-induced acute renal failure (ARF): optimization of the duration of UN dosing.

Authors:  P Venkatesh; T Harisudhan; Hira Choudhury; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Oct-Dec       Impact factor: 2.441

Review 6.  Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.

Authors:  A Mary Vilay; Mariann D Churchwell; Bruce A Mueller
Journal:  Crit Care       Date:  2008-11-12       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.